MRK

Ifinatamab deruxtecan (I-DXd)

FDA PDUFA Target Action Date · Merck & Co., Inc.

Saturday, October 10, 2026

84 days away

Drug Information

Drug Name: Ifinatamab deruxtecan (I-DXd) (CT.gov)
Application Type: BLA
FDA Designations: Priority ReviewBreakthroughOrphan Drug
Indication: Extensive-stage small cell lung cancer (ES-SCLC) after platinum chemo

Filing Details

Company: Merck & Co., Inc. →
Stock Ticker: MRK
SEC CIK: 0000310158
Source: Company IR →

What is a PDUFA Date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.

Standard Review: 10 months from filing acceptance
Priority Review: 6 months from filing acceptance
Possible Outcomes: Approval, Complete Response Letter (CRL), or extension

Explore Merck & Co., Inc.

View Merck & Co., Inc.'s full pipeline, approved drugs, and clinical trials.

View Pipeline → FDA Calendar →

Data sourced from SEC EDGAR filings. Last updated: 2026-04-20. Report an issue